Latest Breaking News On - Erical mayer - Page 1 : comparemela.com

Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

The Role of Elacestrant in Breast Cancer

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

Testing for ESR1 Mutations in Breast Cancer

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Important takeaways in breast cancer from ESMO 2022